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to the outcome in CCBT, and both credibility and expectancy
tend towards signiﬁcance in the TAU group. Credibility and
expectancy do not contribute to the outcomes of the combined
treatment. CONCLUSIONS: Patients’ initial belief about the
success of their depression treatment can inﬂuence the outcome.
Taking the patient’s pre-treatment expectancy and credibility
into account may contribute to a more effective treatment.
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DECLINE IN DEPRESSIONTREATMENT PERSISTS AFTER FDA
ANTIDEPRESSANT WARNINGS
Libby AM, Orton HD,Valuck RJ
University of Colorado Denver, Aurora, CO, USA
OBJECTIVES: To measure the persistence over time of
intended and unintended effects on community based depres-
sion treatment in the U.S. associated with the FDA warnings on
antidepressants and suicidality. In October 2003 the U.S. FDA
issued a Public Health Advisory about the risk of suicidality for
pediatric patients on SSRI antidepressants; a boxed warning
and medication guide were implemented in February 2005, and
later extended to young adults aged 19–24. Unintended
declines in diagnosis and non-SSRI substitute treatment have
been shown immediately following the advisory both for pedi-
atric patients, and for adult patients not targeted by the warn-
ings. Whether those changes persisted is unknown.
METHODS: Pediatric, young adult, and adult cohorts with
newly diagnosed episodes of depression were created using a
national, integrated managed care claims (commercially avail-
able from PHARMetrics®, a Unit of IMS, Inc.) from July
1999-June 2006 (n = 55,218 youth; 44,141 young adults;
394,524 adults patients with new episodes). Time series analy-
ses compared post-FDA advisory trends to expected trends
based on pre-advisory patterns. RESULTS: Young adult and
adult populations mirrored changes in pediatric depression care
after the FDA advisory. Reductions in national rates of depres-
sion treatment were substantial, returning national diagnosing
rates to 1999 levels for pediatric patients and to 2003 levels for
adults. Primary care providers continued signiﬁcant reductions
in new diagnoses of depression (50% lower for pediatric, 40%
lower for young adult, 30% lower for adult). Substitute care by
psychiatrists or psychologists, psychotherapy, and anxiolytic
and atypical antipsychotic medication use did not signiﬁcantly
change from pre-advisory trends. CONCLUSIONS: Declines in
depression diagnosis continued after the advisory. Substitute
care did not compensate. Spillover to adults continued. Results
suggest that the unintended effects were substantial, diffuse,
and non-transitory in a large national population. Policy
actions are required to counter the unintended consequences of
reduced depression treatment.
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PILOT SURVEY OF ADVERSE EVENT MANAGEMENT
ASSOCIATED WITH ANTIPSYCHOTIC USE: THE NEGLECTED
DIMENSION IN RESOURCE USE IMPLICATIONS (A UK
PERSPECTIVE)
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OBJECTIVES: A pilot survey was conducted to determine which
NHS services and resources may possibly be impacted in the
management of adverse events (ADEs) related to antipsychotic
use. METHODS: Ten UK mental health specialists were inter-
viewed. The six-question survey advised participants to assume
that patients’ psychotic symptoms were controlled or that it was
too early in therapy to determine efﬁcacy. The ADEs considered
were limited to those identiﬁed by NICE as most troublesome,
i.e. sedation, extrapyramidal symptoms (EPS), weight gain and
sexual dysfunction. RESULTS: The most common routine tests
performed were: full blood count, glucose, cholesterol and
weight. Action was prompted for sedation and sexual dysfunc-
tion only if the patient raised a concern. For weight gain and EPS,
clinician and patient concerns were given equal consideration.
Actions taken in order of preference were: sedation—decrease
dose, change timing, switch treatment; EPS—decrease dose, add
anticholinergic, switch treatment; weight gain—switch treat-
ment, decrease dose; sexual dysfunction—decrease dose, switch
treatment, add sildenaﬁl. Referrals were mentioned in all
responses but were most commonly associated with weight gain
and sexual dysfunction. Most common tests requested as a result
of an ADE assessment were: glucose, weight, cholesterol and
prolactin. Switching treatment was the most common action in
response to positive tests results for any ADE. CONCLUSIONS:
This pilot survey highlights that ADEs could play a substantial
role in treatment costs given the potential use of resources linked
to their observation, diagnosis and management. As such, in
order to comprehensively calculate the cost-effectiveness of any
antipsychotic treatment, acquisition costs as well as costs asso-
ciated with potential adverse event management should be con-
sidered. To conﬁrm the ﬁndings of this survey, further in-depth
research is warranted.
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OBJECTIVES: To fully describe patients’ characteristics, man-
agement patterns, predictive recurrence factors and economic
impact of health care attention of bipolar patients population in
Spain. The description of the sample of an ongoing cohort study
is being presented. METHODS: Prospective observational
cohort study with a follow-up of 12 months including consecu-
tive outpatients diagnosed of Bipolar Disorder I or II (DSM-IV-
TR), stabilized for at least 2 months, who had at least a mood
disorder episode (depression, mania, hypomania or mixed) in the
last year. RESULTS: A total of 571 patients were included,
60.1% women. Mean age was 47.4 years (SD 13.1). Only 37.5%
were active workers, up to 5.4% were having temporal disability
leave and 16.2% were permanent disabled for working. Regard-
ing study disease, 75% were bipolar I and mean time since
diagnosis was 12.3 years (SD 10.5), although time since ﬁrst
mood episode compatible with bipolar diagnose was 16.3 years
(SD 11.2). Mean mood episode number since disease onset was
10.6 (SD 9.3). Up to 74.1% of patients had been hospitalised
during the disease evolution, mean times were 3.6 (SD 3.3).
21.3% of patients have had a suicide attempt. Regarding the
baseline evaluation, 29.9% of patients were not free of mood
symptoms even being stabilized for at least two months, present-
ing more than two mania symptoms (10.6%) and more than 2
depression symptoms (18.2%). CONCLUSIONS: Even in the
stabilization phase of the disease there is an important symptoms
load. Although depressive symptoms are more frequent than
manic symptoms, both subsyndromal symptoms are present in
euthimic bipolar patients. Bipolar disorder is a relevant chronic
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condition in terms of disease burden, since it affects young people
affecting productivity with a high rate of disability. Hospitalisa-
tions are needed in almost 75% of patients and more than 3
times during disease evolution (mean 12 years). Further knowl-
edge about potentially preventable factors associated with sever-
ity and disease cost and burden would be of extreme value.
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OBJECTIVES: In the treatment of depression several antidepres-
sants are applied, mainly TZA, SSRI and SNRI. These sub-
stances have a different spectrum of activity and side effects,
particularly newer substances are often approved for speciﬁc
indications. Taking SNRI as an example, it is of interest in how
far the indication spectrum is therapeutically utilized by physi-
cians in everyday practice. METHODS: A retrospective cohort
study using claims data of a sickness fund, analysed beneﬁciaries
who received at least one SNRI prescription during the obser-
vation period from January 1, 2004 until December 31, 2004.
ICD-10 Codes from the ﬁeld of depression, anxiety and panic
patients, as well as affective disorders were clustered into diag-
nosis groups which represented potential ﬁelds of indication for
SNRI therapy. The distribution of diagnoses groups over the
indication spectrum was broken down into health care sectors
and represented and analyzed with the help of Venn diagrams.
RESULTS: From 1,478,978 beneﬁciaries n = 2,481 (0.17%) had
at least one prescription of Venlafaxin as the only available
SNRI in 2004. A total of 75.7% of them had a depression
diagnoses, 39.9% received SSRI for relapse prevention. From n
= 2,252 beneﬁciaries with a depression diagnosis and SNRI pre-
scriptions, A total of 22.8% have been treated due to indications
(depression in combination with anxiety) for which only Ven-
lafaxin has been approved. 39.7% have been treated due to an
indication (maintenance therapy and relapse prevention of
depressive disorders) for which besides Venlafaxin only Sertralin
was approved. CONCLUSIONS: One out of four depressive
patients treated currently with Venlafaxine could not be treated
with SSRIs due to the speciﬁc pharmacological proﬁle. Main-
taining the full spectrum of pharmacotherapy, in this example
Venlafaxine for treating depression, will enable physicians treat-
ing patients as adequate as possible to the individual patient’s
condition.
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OBJECTIVES: When patients do not respond to their initial
treatment, the physician can increase the initial dose, switch to
another treatment or add another treatment. This analysis aims
at comparing the different strategies after initiation of escitalo-
pram 10mg in patients treated for Major Depressive Disorder
(MDD). METHODS: Adult MDD patients initiated on escitalo-
pram 10mg, who either increased to 20mg (dose-increased
patients) or switched to (switchers) or were added another anti-
depressant (combination patients), were identiﬁed in the Phar-
Metrics US claims Database (2003–2006). Patients with early
dose increase (before 14 days) were excluded as it was consid-
ered as a scheduled dose titration. Patients’ characteristics at
treatment initiation and treatment outcomes three months after
treatment initiation were compared: treatment persistence or
change, health care resource use and associated costs. Multi-
variate regression analyses were performed to adjust for patient
characteristics and baseline resource use. RESULTS: A total of
8811 patients started with escitalopram 10 mg of which 51%
increased to 20 mg, 29% switched and 20% had a combina-
tion. Mean time to treatment change was 42 days for dose
increase, 36 days for switch (p < 0.001) and 30 days for com-
bination (p < 0.001). Three months after treatment initiation,
dose-increased patients had higher 3-month persistence com-
pared with switchers or combination patients, even when con-
sidering a time-event interaction. Switchers and combination
patients had a higher rate of subsequent/second switch and/or
combination (17.7% and 71.1% respectively), compared with
dose-increased patients (9.6%). Costs of both switchers and
combination patients were higher than those of dose-increased
patients (respectively: +US$124, adjusted RR = 1.1, 95%CI =
[1.0–1.2]; and +US$1060, adjusted RR = 1.3, 95%CI = [1.2–
1.5]). CONCLUSIONS: Increasing the dose of escitalopram
from 10 to 20mg was associated with fewer further changes in
treatment and with lower costs than switching or adding
another antidepressant. For patients who do not respond well to
their initial dose, dose increase should be considered before any
other strategy.
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OBJECTIVES: The study of new patients in a speciﬁc specialty
offered another insight into the epidemiology of diseases and the
mode of health care delivery. The aim of the study was to inves-
tigate the spectrum of diagnoses and medications among the
patients who visited the psychiatric clinics for the ﬁrst time in
Taiwan. METHODS: The data sources came from the historical
claims datasets of 1,000,000-person cohort from 1996 to 2006,
offered by the National Health Insurance Research Database in
Taiwan. The focus was on the patients who had never visited any
psychiatric clinic from 1996 to 2005 and had visited one in 2006.
The analyses of these patients’ ﬁrst visits included the distribu-
tions of the age, sex, primary diagnosis in codes of ICD-9-CM
(the International Classiﬁcation of Diseases, 9th Revision, Clini-
cal Modiﬁcation) and prescribed drugs classiﬁed into ATC (Ana-
tomical Therapeutic Chemical) codes. RESULTS: Among the
1,000,000-person cohort, 8,226 patients (4,393 females and
3,833 males; mean age 39.4  22.5 [SD] years) had their ﬁrst
visits to one of 330 psychiatric clinics in 2006. Among these new
patients, 1460 were under age 18 and 1352 over age 65. Neu-
rotic disorders (ICD-9-CM: 300) were most frequently seen diag-
noses in 3117 visits, followed by affective psychoses (296) in 918
visits and adjustment reaction (309) in 629 visits. The top 10
diagnostic groups accounted for 83.5% of all new visits. Medi-
cations had been prescribed in 6610 (80.3%) visits with an
average of 2.4  1.2 drug items. The most frequently prescribed
drug groups were antidepressants (ATC: N06A) in 3651 visits,
anxiolytics (N05B) in 3212 visits, hypnotics and sedatives
(N05C) in 3125 visits and antipsychotics (N05A) in 979 visits.
CONCLUSIONS: The people in Taiwan seemed unafraid of
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